

## Supplement Documents for Results FY2007

### Astellas Pharma Inc.

- Financial Results of FY2007
- Pipeline list

Cautionary statement regarding forward-looking information

*This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.*

## 1. Detailed Information for Operating Results

rounddown under 0.1 billion yen

	Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Net Sales	920.6	972.5	51.9	5.6%
Cost of Sales	284.0	279.3	-4.7	-1.7%
Ratio of Net Sales	30.9%	28.7%		
Gross Profit	636.5	693.2	56.6	8.9%
SG&A	446.0	417.3	-28.7	-6.4%
Ratio of Net Sales	48.4%	42.9%		
Reserch and Development	167.9	134.4	-33.4	-19.9%
SG&A excluding R&D	278.1	282.8	4.7	1.7%
Advertising and Sales Promotion	77.4	83.0	5.6	7.3%
Salaries, Bonuses and Allowances	117.0	120.1	3.1	2.7%
Other	83.6	79.6	-3.9	-4.8%
Operating Income	190.5	275.9	85.3	44.8%
Ratio of Net Sales	20.7%	28.4%		
Non Operating Income	13.8	24.8	11.0	79.4%
Equity in earnings	1.1	7.9	6.8	587.0%
Non Operating Expenses	6.5	16.5	10.0	152.6%
Foreign Exchange Loss	3.5	14.8	11.2	313.7%
Ordinary Income	197.8	284.1	86.3	43.7%
Ratio of Net Sales	21.5%	29.2%		
Special Gain	41.0	13.3	-27.7	-67.6%
Gain on Sale of Subsidiaries' Shares	21.2	-	-21.2	-
Special Loss	27.1	28.7	1.6	5.9%
Closure of Business Bases	17.6	3.3	-14.3	-81.3%
Special Retirement Benefits	1.2	12.9	11.7	960.4%
Other	8.2	12.4	4.2	51.0%
Income before Income Taxes	211.7	268.7	57.0	26.9%
Income Taxes	78.5	89.1	10.6	13.5%
Minority Interests	1.8	2.1	0.2	13.6%
Net Income	131.2	177.4	46.1	35.2%
Ratio of Net Sales	14.3%	18.2%		

Forecasts

Forecasts

Mar 09 2Q	Change (%)	Mar 09 Full Year	Change (%)
470.0	-2.8%	962.0	-1.1%
83.0	33.3%	161.0	19.7%
114.0	-23.0%	232.0	-15.9%
24.3%		24.1%	
122.0	-19.5%	246.0	-13.4%
26.0%		25.6%	
79.0	-11.2%	159.0	-10.4%
16.8%		16.5%	

## 2. Segment Information by Business

billion yen

		Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Sales	Consolidated	920.6	972.5	51.9	5.6%
	Pharmaceutical	918.5	971.5	52.9	5.8%
	Ratio of Net Sales	99.8%	99.9%		
	Other	2.0	1.0	-0.9	-48.2%
	Ratio of Net Sales	0.2%	0.1%		

## 3. Overseas Sales

billion yen

		Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Overseas Sales		450.0	489.5	39.5	8.8%
	Ratio of Net Sales	48.9%	50.3%		
	North America	223.2	247.1	23.9	10.7%
	Ratio of Net Sales	24.2%	25.4%		
	Europe	182.7	195.6	12.8	7.0%
	Ratio of Net Sales	19.9%	20.1%		
	Asia and others	44.0	46.8	2.7	6.2%
	Ratio of Net Sales	4.8%	4.8%		

Mar 09 2Q	Change (%)	Mar 09 Full Year	Change (%)
231.7	-6.4%	466.9	-4.6%
49.3%		48.5%	

#### 4. Segment Information by Region

billion yen

		Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)	Mar 09 2Q	Change (%)	Mar 09 Full Year	Change (%)
Sales		920.6	972.5	51.9	5.6%	470.0	-2.8%	962.0	-1.1%
Japan		501.6	505.5	3.9	0.8%	244.0	-2.1%	506.9	0.3%
Ratio of Net Sales		54.5%	52.0%			51.9%		52.7%	
North America		173.5	194.5	20.9	12.1%	93.7	-3.9%	189.8	-2.4%
Ratio of Net Sales		18.9%	20.0%			19.9%		19.7%	
Europe		219.6	244.6	24.9	11.4%	117.3	-4.7%	233.6	-4.5%
Ratio of Net Sales		23.9%	25.2%			25.0%		24.3%	
Asia		25.7	27.8	2.1	8.3%	15.1	9.1%	31.7	14.0%
Ratio of Net Sales		2.8%	2.9%			3.2%		3.3%	
Operating Income		190.5	275.9	85.3	44.8%	114.0	-23.0%	232.0	-15.9%
Japan		116.6	176.0	59.3	50.9%				
Ratio of Net Sales		61.2%	63.8%						
North America		51.5	56.3	4.7	9.2%				
Ratio of Net Sales		27.1%	20.4%						
Europe		23.7	41.0	17.2	72.5%				
Ratio of Net Sales		12.5%	14.9%						
Asia		3.7	2.7	-0.9	-26.6%				
Ratio of Net Sales		2.0%	1.0%						
Eliminations		-5.2	-0.2	4.9					

#### 5. Exchange Rate

yen

	Mar 07 Ave	Mar 08 Ave	Mar 07 End	Mar 08 End	Mar 09 2Q	Mar 09 Full Year
Yen/USD	117	114	118	100	100	100
Yen/EUR	150	162	157	158	150	150

\* Exchange rate fluctuation had a positive impact on net sales and operating income in Mar 08 by 12.8 billion yen and 11.4 billion yen, respectively.

## 6.Per Share Information

	Mar 07 Full Year	Mar 08 Full Year
The number of share issued (thousand)	563,964	518,964
Treasury Stocks (thousand)	49,593	20,881
The number of share issued after deducting Treasury Stock	514,371	498,083
Earnings per share (Yen)	244.07	349.89
Dividend per share (Yen)	80	110
Return on Equity (%)	11.3%	16.1%
Dividend on Earnings (%)	3.7%	5.0%

Mar 09 Full Year
---------------------

319.22
120

## 7.Research and Development Expenses

billion yen

	Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Research and Development	167.9	134.4	-33.4	-19.9%
Ratio of Net Sales	18.2%	13.8%		

Mar 09 2Q	Change (%)	Mar 09 Full Year	Change (%)
83.0	33.3%	161.0	19.7%
17.7%		16.7%	

## 8.Addition to Property, Plant and Equipment

billion yen

	Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Addition to Property, Plant and Equipment				
Consolidated	32.3	26.4	-5.8	-18.2%
Parent	19.6	15.8	-3.7	-19.2%
Depreciation(Tangible)				
Consolidated	24.2	22.5	-1.6	-7.0%
Parent	8.1	8.6	0.5	6.5%
Depreciation(Intangible)				
Consolidated	9.7	12.6	2.8	29.4%
Parent	4.4	5.2	0.8	18.3%

Mar 09 Full Year	Change (%)
45.4	71.6%
27.3	21.0%
15.2	20.5%

## 9.Employee

	Mar 07 Ending	Mar 08 Ending
Total	13,900	13,666
Japan	7,900	7,453
North America	1,800	2,084
Europe	3,300	3,177
Asia	900	952
Total Medical Representatives	4,900	5,000

## 10.Shareholders

	Mar 07 Ending	Mar 08 Ending
Banks	34.7%	34.1%
Securities	2.8%	3.7%
Other companies	3.6%	3.8%
Foreign companies	42.7%	46.6%
Individuals and others	7.4%	7.7%
Treasury Stock	8.8%	4.0%

## 11.Detailed Pharmaceutical Segment Information

### 1)Consolidated sales of major products

billion yen

	Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)	Mar 09 2Q	Change (%)	Mar 09 Full Year	Change (%)
Prograf	175.4	203.0	27.6	15.8%	96.7	-1.0%	191.4	-5.8%
Sales by Astellas	170.1	198.2	28.1	16.5%	94.1	-1.6%	186.9	-5.7%
Japan	19.0	24.6	5.5	29.2%	12.7	7.6%	26.2	6.4%
North America	88.0	97.2	9.1	10.4%	41.2	-14.3%	80.4	-17.3%
Europe	52.7	65.3	12.5	23.9%	34.8	14.0%	68.7	5.2%
Asia	10.3	11.0	0.7	7.6%	5.4	3.4%	11.6	4.4%
Exports to third parties(Europe)	5.2	4.8	-0.4	-8.5%	2.6	27.8%	4.5	-7.5%
Harnal	127.0	122.4	-4.5	-3.6%	58.8	-10.5%	112.3	-8.3%
Sales by Astellas	81.4	75.7	-5.7	-7.1%	33.5	-11.7%	67.2	-11.2%
Japan	38.5	37.5	-1.0	-2.6%	18.0	-5.2%	35.8	-4.7%
Europe	35.3	29.5	-5.7	-16.3%	11.2	-24.3%	22.5	-24.0%
Capsule	18.8	12.3	-6.5	-34.7%	4.0	-33.2%	8.0	-34.7%
Omnice OCAS	16.4	17.2	0.7	4.8%	7.1	-18.0%	14.4	-16.3%
Asia	7.5	8.2	0.6	8.4%	4.2	3.9%	8.7	5.7%
Bulk and Royalties	45.5	46.7	1.2	2.7%	25.3	-8.8%	45.1	-3.7%
Vesicare	36.2	60.1	23.8	65.8%	34.3	24.8%	74.0	23.0%
Japan	6.2	13.5	7.3	117.6%	8.5	52.3%	17.2	27.3%
North America	17.6	27.7	10.0	57.1%	15.5	16.7%	34.9	25.9%
Europe	12.3	18.5	6.2	50.3%	10.0	16.6%	20.9	12.4%
Asia	0.0	0.3	0.2	560.7%	0.3	446.2%	1.0	197.7%
Funguard/Mycamine	16.5	17.8	1.3	8.0%	9.0	2.2%	18.5	3.5%
Japan	12.8	12.8	0.0	0.2%	6.2	-5.4%	12.3	-4.1%
North America	3.5	4.7	1.1	32.3%	2.6	20.5%	5.6	18.9%
Asia	0.0	0.2	0.2	270.9%	0.2	165.6%	0.5	87.8%
Protopic	14.7	16.4	1.7	12.0%	8.5	5.2%	17.5	6.1%
Japan	2.6	2.7	0.0	0.9%	1.4	-2.3%	2.8	2.9%
North America	7.1	8.0	0.9	13.1%	4.0	3.4%	8.2	2.1%
Europe	4.5	5.2	0.6	15.2%	2.7	9.6%	5.7	10.0%
Asia	0.3	0.4	0.1	49.6%	0.4	52.6%	0.7	47.3%

- Sales of products in Japan are shown in a gross sales basis.

## 2) Consolidated Sales of Other Products

billion yen

Rx Sales in Japan <Global products>	Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)	Mar 09 2Q	Change (%)	Mar 09 Full Year	Change (%)
Prograf	19.0	24.6	5.5	29.2%	12.7	7.6%	26.2	6.4%
Harnal	38.5	37.5	-1.0	-2.6%	18.0	-5.2%	35.8	-4.7%
Vesicare	6.2	13.5	7.3	117.6%	8.5	52.3%	17.2	27.3%
Funguard	12.8	12.8	0.0	0.2%	6.2	-5.4%	12.3	-4.1%
Protopic	2.6	2.7	0.0	0.9%	1.4	-2.3%	2.8	2.9%
<Domestic Products>								
Lipitor	94.7	97.7	2.9	3.2%	49.2	1.1%	99.2	1.5%
Gaster	62.2	60.9	-1.3	-2.2%	28.4	-7.5%	56.0	-8.1%
Micardis	50.3	62.6	12.2	24.4%	31.2	3.1%	64.5	3.0%
Cefzon	14.7	14.5	-0.1	-1.2%	5.8	-12.1%	11.6	-20.2%
Myslee	19.4	21.5	2.1	11.1%	11.6	8.9%	23.4	8.5%
Vaccines	13.3	15.7	2.4	18.1%	2.1	-52.8%	13.5	-14.5%
Seroquel	16.8	19.2	2.3	14.2%	9.8	2.5%	19.6	1.9%
Frاندول	12.3	12.0	-0.2	-2.4%	5.9	-3.1%	11.5	-4.3%
Perdipine	7.5	6.6	-0.8	-11.8%	2.9	-12.9%	5.7	-14.1%
Luvox	11.1	11.0	-0.0	-0.5%	5.2	-8.7%	10.3	-7.1%
Dorner	7.8	7.4	-0.4	-5.3%	3.5	-7.7%	6.8	-8.5%
Dogmatyl	7.3	7.0	-0.2	-4.0%	3.4	-6.2%	6.7	-5.3%
Cefamezin	6.6	6.6	-0.0	-0.2%	3.1	-8.4%	6.0	-9.6%
Targocid	6.4	6.3	-0.1	-2.2%	3.1	-4.1%	6.0	-5.3%
Intal	7.9	7.0	-0.9	-11.9%	2.3	-11.2%	5.2	-26.2%
Nivadil	5.4	4.5	-0.8	-16.2%	2.1	-12.7%	3.9	-14.9%
Cibenol	5.1	5.2	0.0	1.5%	2.5	-5.0%	4.9	-5.8%
Nasea	4.7	4.7	-0.0	-1.2%	2.3	-6.3%	4.5	-4.9%
Starsis	4.3	4.3	0.0	0.1%	2.2	0.5%	4.4	1.4%
Celecox (Launched in June 2007)	-	3.7	3.7	-	2.8	121.3%	6.3	67.7%
Geninax (Launched in October 2007)	-	3.7	3.7	-	2.1	-	6.6	75.9%
<b>Total Rx Sales In Japan</b>	<b>455.2</b>	<b>478.2</b>	<b>22.9</b>	<b>5.0%</b>	<b>237.5</b>	<b>1.9%</b>	<b>489.5</b>	<b>2.4%</b>

- Sales of products in Japan are shown in a gross sales basis.



RX Sales in North America and EU		billion yen			
		Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Scan*	(North America)	37.1	37.6	0.5	1.4%
AmBisome	(North America)	8.8	7.6	-1.2	-13.6%
Vaprisol	(North America)	0.1	0.9	0.7	394.7%
Amevive	(North America)	2.4	2.2	-0.1	-7.5%
Eligard	(Europe)	5.9	9.2	3.3	56.8%

\* Adenoscan + Lexiscan

Mar 09 2Q	Change (%)	Mar 09 Full Year	Change (%)
18.8	-5.5%	38.9	3.3%
3.5	-5.8%	6.8	-10.7%
0.8	64.4%	1.8	95.9%
0.8	-31.4%	1.8	-19.8%
5.2	18.2%	11.3	22.5%

Export Sales		billion yen			
		Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Cefzon	Overseas(Exports to third party)	10.8	5.3	-5.4	-50.9%
Cefspan	Overseas(Exports to third party)	5.7	6.4	0.7	13.2%

Mar 09 2Q	Change (%)	Mar 09 Full Year	Change (%)
0.4	-89.1%	0.8	-84.3%
2.4	-24.0%	5.0	-23.2%

## Sales in Europe and North America

Unit:M\$

North America	Mar 07	Mar 08	Change	Change (%)	Mar 09	Change	Mar 09	Change
	Full Year	Full Year			2Q	(%)	Full Year	(%)
Sales	1,483	1,702	218	14.8%	937	14.6%	1,898	11.5%
Prograf	752	850	98	13.1%	412	2.3%	804	-5.5%
Scan*	317	329	12	3.8%	188	12.8%	389	18.1%
AmBisome	75	66	-8	-11.6%	35	12.5%	68	2.1%
Protopic	60	70	9	15.8%	40	23.4%	82	16.7%
VESicare	150	242	91	60.8%	155	39.3%	349	43.8%
Mycamine	30	41	10	35.5%	26	43.8%	56	35.9%
Vaprisol	1	7	6	406.5%	8	96.1%	18	123.9%
Amevive	20	19	-1	-5.3%	8	-18.2%	18	-8.4%

\* Adenoscan + Lexiscan

Unit:M€

Europe	Mar 07	Mar 08	Change	Change (%)	Mar 09	Change	Mar 09	Change
	Full Year	Full Year			2Q	(%)	Full Year	(%)
Sales	1,463	1,514	50	3.5%	782	3.2%	1,557	2.8%
Harnal	538	472	-66	-12.3%	242	-7.7%	447	-5.3%
Sales by Astellas	235	182	-52	-22.2%	74	-18.0%	150	-18.1%
Capsule	126	76	-49	-39.3%	27	-27.7%	54	-29.7%
OCAS	109	106	-2	-2.7%	48	-11.3%	96	-9.8%
Bulk and Royalty	303	289	-13	-4.6%	167	-2.2%	298	2.8%
Prograf	386	434	47	12.3%	248	23.8%	486	12.0%
Sales by Astellas	351	404	53	15.1%	232	23.3%	458	13.3%
Exports to third parties	35	29	-5	-15.3%	16	31.4%	28	-5.8%
Vesicare	82	114	32	39.7%	66	26.2%	139	21.1%
Protopic	30	32	2	7.0%	18	18.6%	38	18.5%
Eligard	39	57	17	45.7%	35	27.9%	76	31.9%

## 12.Consolidated Balance Sheets

						Billion yen	
		31-Mar-08		31-Mar-07		Change	Comments
		Amount	Composition	Amount	Composition		
<b>Assets</b>		<b>1,439.1</b>	<b>100.0%</b>	<b>1,470.7</b>	<b>100.0%</b>	<b>-31.5</b>	
<b>Current assets</b>		<b>977.2</b>	<b>67.9%</b>	<b>965.9</b>	<b>65.7%</b>	<b>11.2</b>	
	Cash on hand and in banks	248.5		223.3		25.1	
	Trade notes and accounts receivable	222.0		231.0		-9.0	
	Marketable securities	293.5		284.3		9.2	
	Inventories	91.4		90.9		0.4	
	Deferred tax assets	68.0		58.1		9.8	
	Other	54.3		78.5		-24.2	
	Allowance for doubtful receivable	-0.6		-0.5		-0.0	
<b>Fixed assets</b>		<b>461.8</b>	<b>32.1%</b>	<b>504.7</b>	<b>34.3%</b>	<b>-42.8</b>	
<b>Property, plant and equipment</b>		<b>179.8</b>	<b>12.5%</b>	<b>194.5</b>	<b>13.2%</b>	<b>-14.6</b>	
	Buildings and structures	78.6		88.9		-10.3	
	Machinery, equipment and vehicles	26.9		30.6		-3.6	
	Tools, furniture and fixtures	17.2		22.3		-5	
	Land	31.2		35.6		-4.3	
	Construction in progress	25.5		16.7		8.7	
	Other	0.2		0.2		-0.0	
<b>Intangible fixed assets</b>		<b>67.9</b>	<b>4.7%</b>	<b>41.5</b>	<b>2.8%</b>	<b>26.4</b>	----- Goodwill associated with the acquisition of Agensys' shares
<b>Investments and other assets</b>		<b>214.0</b>	<b>14.9%</b>	<b>268.6</b>	<b>18.3%</b>	<b>-54.6</b>	
	Investment securities	157.7		210.6		-52.9	
	Long-term loans receivable	1.9		2.2		-0.3	
	Deferred tax assets	39.7		37.1		2.5	
	Other	14.7		18.6		-3.8	
	Allowance for doubtful receivables	-0.2		-0.1		-0.0	

	31-Mar-08		31-Mar-07		Change	Comments
	Amount	Composition	Amount	Composition		
<b>Liabilities and Shareholders' Equity</b>	<b>1,439.1</b>	<b>100.0%</b>	<b>1,470.7</b>	<b>100.0%</b>	<b>-31.5</b>	
<b>Liabilities</b>	<b>328.2</b>	<b>22.8%</b>	<b>371.7</b>	<b>25.3%</b>	<b>-43.4</b>	
<b>Current liabilities</b>	<b>284.5</b>	<b>19.8%</b>	<b>308.8</b>	<b>21.0%</b>	<b>-24.3</b>	
Trade notes and accounts payable	70.0		73.0		-2.9	
Short-term loans payable	-		1.6		-1.6	
Other accounts payable	107.4		108.8		-1.3	
Accrued expenses	56.2		65.7		-9.4	
Accrued income taxes	38.0		44.3		-6.3	
Accrued consumption taxes	2.0		2.0		0.0	
Deferred tax liabilities	0.0		-		0.0	
Accrued bonus for directors	0.1		0.1		0.0	
Allowance for sales rebates and others	5.0		4.0		1.0	
Other	5.3		9.0		-3.7	
<b>Long-term liabilities</b>	<b>43.7</b>	<b>3.0%</b>	<b>62.8</b>	<b>4.3%</b>	<b>-19.1</b>	
Deferred tax liabilities	0.2		0.5		-0.3	
Accrued retirement benefits for employees	17.4		18.4		-0.9	
Accrued retirement benefits for directors	0.0		0.0		0.0	
Other	25.9		43.7		-17.8	
<b>Shareholders' equity</b>	<b>1110.8</b>	<b>77.2%</b>	<b>1,098.9</b>	<b>74.7%</b>	<b>11.8</b>	
Common stock	103.0	7.2%	103.0	7.0%	0.0	
Additional paid-in capital	176.8	12.3%	176.8	12.0%	0.0	
Retained earnings	917.2	63.6%	1,006.6	68.4%	-89.4	
Treasury stock	-104.1	-7.2%	-241.9	-16.4%	137.7	{ - Cancellation of 45 million of treasury stock - Share buyback implemented (16.3 million shares)
Unrealized holding gain on securities	27.8	1.9%	38.0	2.6%	-10.2	
Translation adjustments	-10.8	-0.7%	15.7	1.1%	-26.5	
Stock acquisition rights	0.6	0.0%	0.2	0.0%	0.3	
Minority interests	0.3	0.0%	0.3	0.0%	-0.0	

### 13.Detailed Parent Company Information

P/L

billion yen

	Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Sales	593.7	611.2	17.4	2.9%
Cost of Sales	219.3	221.8	2.5	1.1%
Ratio of Net Sales	36.9%	36.3%		
Gross Profit	374.3	389.3	14.9	4.0%
SG&A	267.2	221.1	-46.1	-17.3%
Ratio of Net Sales	45.1%	36.2%		
Advertising and sales promotion	25.5	26.3	0.7	3.1%
Reserch and Development	144.7	104.6	-40.0	-27.7%
Salaries, Bonuses and Allowances	58.1	55.4	-2.7	-4.7%
Other	38.8	34.6	-4.1	-10.7%
Operating Income	107.1	168.2	61.0	57.0%
Ratio of Net Sales	18.0%	27.5%		
Non Operating Income	7.3	21.3	13.9	188.7%
Non Operating Expenses	1.9	1.3	-0.6	-31.8%
Ordinary Income	112.5	188.2	75.6	67.2%
Ratio of Net Sales	19.0%	30.8%		
Special Gain	40.9	3.2	-37.7	-92.2%
Gain on Sale of Subsidiaries' Shares	23.2	-	-23.2	-
Special Loss	11.6	17.9	6.3	54.3%
Closure of Business Bases	5.1	-	-5.1	-
Special Retirement Benefits	1.2	11.5	10.3	842.4%
Other	5.2	6.4	1.2	23.0%
Income before Income Taxes	141.8	173.4	31.5	22.2%
Income Taxes	47.6	61.1	13.5	28.5%
Net Income	94.2	112.2	18.0	19.1%
Ratio of Net Sales	15.9%	18.4%		

Sales of Parent company

billion yen

	Mar 07 Full Year	Mar 08 Full Year	Change	Change (%)
Rx	461.6	479.5	17.9	3.9%
Exporting sales (including royalty)	132.1	131.6	-0.4	-0.4%
Royalty	37.3	36.6	-0.7	-2.0%